A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.

被引：0
|
作者：
Bjerregaard, Jon Kroll
Ladekarl, Morten
Jensen, Helle Anita
Vestermark, Lene Weber
Farr, Katherina Podlekareva
Pfeiffer, Per
机构：
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[2] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[3] Odense Univ Hosp, DK-5000 Odense, Denmark
[4] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15238
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Farr, Katherina Podlekareva
    Vestermark, Lene Weber
    Jensen, Helle Anita
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): A randomized phase II trial in advanced pancreatic cancer.
    Heinemann, V
    Hoehler, T
    Seipelt, G
    Wein, A
    Golf, A
    Mahlberg, R
    Schmid, B
    Boeck, S
    Neugebauer, S
    Hochhaus, A
    Grosshadern, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 315S - 315S
  • [3] A phase I/II, nonrandomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab, and capecitabine in patients with metastatic pancreatic cancer.
    Wilmink, J.
    Kordes, S.
    Klumpen, H.
    Richel, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer.
    Stathopoulos, GP
    Aravantinos, G
    Syrigos, K
    Kalbakis, K
    Karvounis, N
    Papakotoulas, P
    Boukovinas, J
    Potamianou, A
    Polyzos, A
    Christophilakis, CH
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [5] Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer
    Merchan, Jaime R.
    Ferrell, Annaporna
    Macintyre, Jessica
    Ciombor, Kristen K.
    Levi, Joe
    Ribeiro, Afonso
    Sleeman, Danny
    Flores, Aurea
    Lopes, Gilberto
    Rocha-Lima, Caio M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (05): : 446 - 450
  • [6] Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
    Bayoglu, Ibrahim Vedat
    Varol, Umut
    Yildiz, Ibrahim
    Muslu, Ugur
    Alacacioglu, Ahmet
    Kucukzeybek, Yuksel
    Akyol, Murat
    Demir, Lutfiye
    Dirican, Ahmet
    Cokmert, Suna
    Yildiz, Yasar
    Karabulut, Bulent
    Uslu, Ruchan
    Tarhan, Mustafa Oktay
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (17) : 7119 - 7123
  • [7] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Roberto Petrioli
    Giandomenico Roviello
    Anna Ida Fiaschi
    Letizia Laera
    Daniele Marrelli
    Franco Roviello
    Edoardo Francini
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 683 - 690
  • [8] A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
    Kanai, Masashi
    Yoshimura, Kenichi
    Asada, Masanori
    Imaizumi, Atsushi
    Suzuki, Chihiro
    Matsumoto, Shigemi
    Nishimura, Takafumi
    Mori, Yukiko
    Masui, Toshihiko
    Kawaguchi, Yoshiya
    Yanagihara, Kazuhiro
    Yazumi, Shujiro
    Chiba, Tsutomu
    Guha, Sushovan
    Aggarwal, Bharat B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 157 - 164
  • [9] Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study
    Petrioli, Roberto
    Roviello, Giandomenico
    Fiaschi, Anna Ida
    Laera, Letizia
    Marrelli, Daniele
    Roviello, Franco
    Francini, Edoardo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 683 - 690
  • [10] Phase II study of gemcitabine, capecitabine and cisplatin in patients with advanced pancreatic cancer.
    Chang, HM
    Kim, TW
    Ahn, JH
    Ryu, MH
    Lee, JS
    Kim, WK
    Kang, YK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 368S - 368S
12345